Femasys’ (FEMY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

Femasys Stock Down 3.4 %

Shares of NASDAQ:FEMY opened at $1.29 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. Femasys has a 52-week low of $0.86 and a 52-week high of $1.84. The company has a market capitalization of $29.54 million, a PE ratio of -1.59 and a beta of -2.85. The company has a fifty day moving average of $1.41 and a 200-day moving average of $1.23.

Femasys (NASDAQ:FEMY) last issued its earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The business had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $1.66 million. On average, equities analysts predict that Femasys will post -0.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Femasys

Several institutional investors and hedge funds have recently added to or reduced their stakes in FEMY. XTX Topco Ltd grew its stake in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the period. Virtu Financial LLC acquired a new stake in shares of Femasys in the fourth quarter valued at about $25,000. Northern Trust Corp raised its position in shares of Femasys by 42.6% during the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Femasys in the fourth quarter worth approximately $30,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.